And other biotech news brought to you by The Readout newsletter
Want to stay on top of the science and politics driving biotech today?
Sign up
to get our biotech newsletter in your inbox.
Grail’s Galleri blood test just failed a make-or-break NHS trial, missing its primary endpoint and reviving the uncomfortable question: Does earlier detection actually change outcomes, or just the timeline for diagnoses?
And there’s more news out of the FDA: The agency has installed an AI industry vet to steer digital health, and new CDER chief Tracy Beth Høeg tells staff she’s keen to revisit SSRIs in pregnancy and scrutinize RSV monoclonals.
Continue to STAT+ to read the full story…
— Source: STAT News (https://www.statnews.com/2026/02/20/biotech-news-element-biosciences-100-dollar-genome/)
